Dr Reddy's Laboratories Price to Free Cash Flow Ratio 2010-2024 | RDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Dr Reddy's Laboratories average price to free cash flow ratio for 2023 was 17.82, a 41.09% increase from 2022.
Dr Reddy's Laboratories average price to free cash flow ratio for 2022 was 30.25, a 60.97% decline from 2021.
Dr Reddy's Laboratories average price to free cash flow ratio for 2021 was 77.51, a 132.41% decline from 2020.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Dr Reddy's Laboratories average price to free cash flow ratio for 2023 was 17.82, a 41.09% increase from 2022.
Dr Reddy's Laboratories average price to free cash flow ratio for 2022 was 30.25, a 60.97% decline from 2021.
Dr Reddy's Laboratories average price to free cash flow ratio for 2021 was 77.51, a 132.41% decline from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
BridgeBio Pharma (BBIO)	$4.4B
Bausch Health Cos (BHC)	$2.9B
Amphastar Pharmaceuticals (AMPH)	$2.2B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$506M
Personalis (PSNL)	$245M
Assembly Biosciences (ASMB)	$96M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$6M
Teligent (TLGT)	$0M